We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

53 hedge funds and large institutions have $118M invested in Eiger BioPharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

6% more funds holding

Funds holding: 50 → 53 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less capital invested

Capital invested by funds: $120M → $118M (-$2.51M)

Holders
53
Holders Change
+3
Holders Change %
+6%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
17
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$3.83M
2
EIM
Essex Investment Management
Massachusetts
+$589K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$570K
4
Renaissance Technologies
Renaissance Technologies
New York
+$554K
5
AG
Algert Global
California
+$515K

Top Sellers

Rank Fund Capital Flow
1
GC
GMT Capital
Georgia
-$3.46M
2
HCM
Highbridge Capital Management
New York
-$1.72M
3
PM
Prosight Management
Texas
-$1.11M
4
UC
Unterberg Capital
New York
-$976K
5
Millennium Management
Millennium Management
New York
-$871K
Name Holding Trade Value Shares
Change 		Change in
Stake
KC
26
Kepos Capital
New York
$432K – – –
PAWC
27
P.A.W. Capital
Connecticut
$420K -$627K -1,833 -61%
WMSA
28
Weiss Multi-Strategy Advisers
New York
$420K +$399K +1,167 New
PCM
29
Prelude Capital Management
New York
$347K +$330K +965 New
CC
30
Caxton Corporation
New Jersey
$306K +$291K +850 New
AAP
31
Ardsley Advisory Partners
Connecticut
$300K – – –
Two Sigma Investments
32
Two Sigma Investments
New York
$299K +$15.1K +44 +6%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$239K -$5.47K -16 -2%
Bank of America
34
Bank of America
North Carolina
$208K +$16.1K +47 +9%
TAM
35
Tocqueville Asset Management
New York
$203K +$193K +563 New
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
$194K +$184K +538 New
DS
37
DRW Securities
Illinois
$177K -$49.6K -145 -23%
Goldman Sachs
38
Goldman Sachs
New York
$130K -$35.2K -103 -22%
PP
39
PDT Partners
New York
$127K -$290K -848 -71%
Morgan Stanley
40
Morgan Stanley
New York
$127K -$203K -594 -63%
Squarepoint
41
Squarepoint
New York
$122K +$116K +340 New
California Public Employees Retirement System
42
California Public Employees Retirement System
California
$120K – – –
AAMU
43
Amundi Asset Management US
Massachusetts
$84K – – –
Wells Fargo
44
Wells Fargo
California
$44K -$1.37K -4 -3%
TRCT
45
Tower Research Capital (TRC)
New York
$20K +$16.1K +47 +588%
UBS Group
46
UBS Group
Switzerland
$11K +$4.79K +14 +82%
MAM
47
Meeder Asset Management
Ohio
$11K +$7.87K +23 +329%
Walleye Trading
48
Walleye Trading
New York
$6K +$5.82K +17 New
APA
49
American Portfolios Advisors
New York
$2.4K +$2.39K +7 New
Citigroup
50
Citigroup
New York
$2K – – –
1
2
3

EIGR Hedge Fund Activity: Q3 2018 in Review

53 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2018, worth a combined $118M — down 2.1% from $120M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new EIGR positions and 8 closed out — a net gain of 3 holders — while 17 added to existing stakes and 10 trimmed.

The largest buyer was 683 Capital Management, adding an estimated $3.83M. The largest seller was GMT Capital, exiting entirely with an estimated $3.46M sold.

  • 53 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2018, up from 50 in Q2 2018.
  • Funds reported $118M of Eiger BioPharmaceuticals, Inc. stock for Q3 2018, down 2.1% quarter-over-quarter.
  • 11 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2018 and 8 closed out, a net change of +3 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2018 was 683 Capital Management, an estimated $3.83M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2018 was GMT Capital, an estimated $3.46M sold.

Based on aggregated 13F filings for Q3 2018.